GBT 440

Drug Profile

GBT 440

Alternative Names: GBT440; GTx-011

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Global Blood Therapeutics
  • Class Antianaemics; Small molecules
  • Mechanism of Action Sickle haemoglobin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • Phase II Idiopathic pulmonary fibrosis
  • Phase I Hypoxia

Most Recent Events

  • 06 Dec 2016 Global Blood Therapeutics completed a phase I trial in Sickle cell anaemia (In volunteers) in USA (PO)
  • 04 Dec 2016 Phase-III clinical trials in Sickle cell anaemia in USA (PO)
  • 04 Dec 2016 Efficacy and safety data from a phase I/II trial in Sickle cell disease presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top